ATX 1.64% 6.2¢ amplia therapeutics limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-44

  1. 437 Posts.
    lightbulb Created with Sketch. 211
    agree. I’m big on looking at comparable trials to see how recruitment went as that’s often a good guide to the scale of the challenge . Take MPACT panc cancer trial I referred to before (gemcitabine + abraxane) . The published study says it took about 3 years with 150 sites to get 860 patients. That’s about 2 patients per site per year. Unless you think there’s a reason why ACCENT can substantially outperform MPACT , then I’d be using that estimate as a guide.
    If that plays out here, with 11 sites, then could take at least a year to get this 26….
 
watchlist Created with Sketch. Add ATX (ASX) to my watchlist
(20min delay)
Last
6.2¢
Change
0.001(1.64%)
Mkt cap ! $17.38M
Open High Low Value Volume
6.1¢ 6.4¢ 6.1¢ $1.594K 26.02K

Buyers (Bids)

No. Vol. Price($)
2 59891 6.1¢
 

Sellers (Offers)

Price($) Vol. No.
6.2¢ 76767 1
View Market Depth
Last trade - 13.50pm 28/06/2024 (20 minute delay) ?
ATX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.